Pfizer Inc. (NYSE: PFE) and Valneva SE (NASDAQ: VALN, PARIS: VLA) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405. The EMA will now begin its assessment of the application for the investigational 6-valent outer surface protein A (OspA)-based vaccine candidate.

The MAA is supported by results from the Phase 3 VALOR ("Vaccine Against Lyme for Outdoor Recreationists") clinical trial. The trial reported encouraging efficacy of more than 70% in preventing Lyme disease cases among participants aged five years and older. The vaccine candidate was well tolerated during the trial, with no safety concerns identified.

Trial Design and Mechanism

The VALOR trial was a multicenter, placebo-controlled, randomized, observer-blinded study conducted across the U.S., Canada, and Europe in areas of high Lyme disease incidence. A total of 9,437 participants were randomized 1:1 to receive either PF-07307405 or a saline placebo. The regimen consisted of four doses: one each at months 0, 2, and 5–9, followed by a fourth dose one year later, shortly before the start of the following Lyme disease season.

PF-07307405 is a multivalent protein subunit vaccine targeting the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria causing Lyme disease. Immunization induces antibodies against six Borrelia OspA serotypes. When a tick feeds on a vaccinated person, these antibodies are ingested and bind to OspA on Borrelia inside the tick, inhibiting the bacterium’s ability to leave the tick and transmit to the human host. The candidate covers the six most prevalent OspA serotypes expressed by Borrelia burgdorferi sensu lato species in North America and Europe.

Market Context and Collaboration

Lyme disease is the most common vector-borne illness in Europe, affecting more than 100,000 people annually. In the U.S., the Centers for Disease Control and Prevention (CDC) estimates approximately 476,000 diagnoses and treatments per year, with 132,000 cases reported annually in Europe from countries with surveillance systems. Currently, there are no approved human vaccines for Lyme disease.

Pfizer and Valneva entered into a collaboration and license agreement in April 2020 for the co-development of PF-07307405. Under the terms, Pfizer holds exclusive rights to manufacture and commercialize the vaccine candidate, assuming regulatory success. Two pivotal Phase 3 trials have been completed for this candidate, which has advanced the furthest along the clinical development timeline for Lyme disease prevention.

Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer at Pfizer, stated that the company looks forward to collaborating with the EMA as the candidate advances through the review cycle. Thomas Lingelbach, CEO and Board member of Valneva, noted that the MAA acceptance represents a major milestone, particularly given that more than 200 million people live in Lyme disease risk areas in Europe.

Pfizer Inc. (NYSE: PFE) will report its second-quarter financial results before the opening bell on Tuesday, August 4. The New York-based pharmaceutical giant faces scrutiny from investors as consensus estimates point to a contraction in profitability, with expected earnings per share of $0.68, down from $0.78 in the corresponding period last year. Revenue forecasts stand at $14.39 billion, slightly below the $14.65 billion reported in the year-ago quarter. These figures suggest continued pressure on margins as the company navigates post-pandemic demand normalization.

Analyst Sentiment Shifts

Despite positive clinical developments, including topline Phase 3 results for LITFULO in patients with nonsegmental vitiligo announced on July 30, analyst sentiment has turned cautious. Shares of Pfizer rose 0.1% to close at $25.03 on Monday, reflecting limited market enthusiasm ahead of the earnings release. Recent actions by Benzinga’s most accurate analysts indicate a downward revision in valuation expectations across multiple firms.

The table above details recent rating changes and price target adjustments. Notably, BMO Capital’s Evan David Seigerman, who maintains a 57% accuracy rate, slashed the price target by $4. Guggenheim’s Vamil Divan, with a 78% accuracy rate, reduced his target by $1. The consistency of these cuts across firms with varying accuracy rates (65% to 78%) suggests a broad-based reassessment of Pfizer’s near-term growth trajectory.

What the Numbers Show

The divergence between positive pipeline news and declining analyst targets highlights a key tension for Pfizer. While the LITFULO approval represents a long-term value driver, it has not yet offset concerns regarding near-term revenue visibility. The consensus revenue estimate of $14.39 billion implies a modest decline from the previous year’s $14.65 billion. Investors will likely focus on whether operational efficiencies or cost-cutting measures can sustain earnings power despite top-line softness. The upcoming report will clarify if the company can maintain its dividend and buyback commitments amidst these headwinds.